PARIS, Oct 22 (Reuters) - French in vitro diagnostics group BioMerieux (BIOX.PA) cut its full-year organic sales growth target again on Friday, citing weakness in the healthcare industry in western Europe and North America. The company said it now expects sales to rise 4.5 percent in 2010, down from a forecast of a 6 percent increase given in September.
